01 / ATLAS
What it is
KPV is the lysine–proline–valine sequence, a tripeptide investigated for its effects on inflammatory signaling. [1]
02 / ATLAS
How it works
In experimental models, the PepT1 transporter enabled KPV to enter cells. Researchers observed reductions in some inflammatory signaling pathways and cytokine secretion. [1]
03 / ATLAS
What research shows
Cell and mouse studies provide a basis for further investigation. They do not demonstrate an effective treatment for ulcerative colitis or Crohn’s disease in people. [1]
04 / ATLAS
Study data
Dalmasso et al., 2008: cell cultures and mouse colitis models, evaluating PepT1 transport and inflammation. Experimental animal doses are not converted into recommendations for humans here. [1]
05 / ATLAS
Safety and observed adverse reactions
The FDA reports a lack of identified human exposure data for KPV and insufficient information to assess safety. [2]
06 / ATLAS
Research status
The evidence presented is preclinical. Clinical efficacy, dose and safety for the discussed indications are not established by the cited study.
07 / REFERENCES
Studies and sources
- Dalmasso et al. · PepT1 and KPV (2008) ↗Original research · cells and animal models
- FDA · Safety information for KPV ↗Official assessment · United States